A Pinto1, M F Almeida1,2, P C Ramos1, S Rocha3, A Guimas3, R Ribeiro3, E Martins3, A Bandeira3, A MacDonald4, J C Rocha1,5,6. 1. Centro de Genética Médica, Centro Hospitalar do Porto (CHP), Porto, Portugal. 2. Unit for Multidisciplinary Research in Biomedicine, Abel Salazar Institute of Biomedical Sciences, University of Porto-UMIB/ICBAS/UP, Porto, Portugal. 3. Unidade de Doenças Metabólicas, Centro Hospitalar do Porto (CHP), Porto, Portugal. 4. Birmingham Children's Hospital, Birmingham, UK. 5. Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal. 6. Centre for Health Technology and Services Research (CINTESIS), Porto, Portugal.
Abstract
BACKGROUND/ OBJECTIVES: Low phenylalanine (PHE), glycomacropeptide-based protein substitute (GMP) is an alternative to traditional L-amino acid supplements (AA) used in the dietary management of phenylketonuria (PKU). In a retrospective, longitudinal study, we report the nutritional status of PKU patients taking AA and GMP. SUBJECTS/ METHODS: Eleven PKU patients aged 27±10 years (1 HPA, 4 mild and 6 classical PKU) on dietary treatment were evaluated (anthropometry, body composition, blood pressure measurements, biochemical markers including vitamin, mineral, lipids, carbohydrates and protein status/metabolism, and nutritional intake assessment) at two different annual reviews. The mean time taking AA was 13±5 months and GMP 13±7 months. Blood phenylalanine (PHE) and tyrosine (TYR) were analysed before and after GMP introduction. RESULTS: Both GMP and AA protein substitutes provided similar protein equivalent intake (0.85 vs 0.75 g/kg/day, P=0.182). In the GMP group, it contributed 57% (27-100%) of the protein substitute intake (with AA delivering the rest of protein substitute intake), providing an additional 34±12 mg/day PHE. Nutritional intake, anthropometry and body composition measurements were similar in both the groups. Median blood PHE did not change (P=0.594), although values within target range improved (36 vs 46%), but this was not statistically significant. Mean blood TYR increased (52.0±19.2 vs 63.2±25.6 μmol/l, P=0.033), and all biochemical markers remained stable, except for a lower A1C haemoglobin (P=0.011). CONCLUSIONS: Partial GMP contribution to total protein substitute intake did not affect nutritional status in patients with PKU. Blood PHE control was not adversely affected. The increased blood TYR after GMP introduction necessitates further study.
BACKGROUND/ OBJECTIVES: Low phenylalanine (PHE), glycomacropeptide-based protein substitute (GMP) is an alternative to traditional L-amino acid supplements (AA) used in the dietary management of phenylketonuria (PKU). In a retrospective, longitudinal study, we report the nutritional status of PKUpatients taking AA and GMP. SUBJECTS/ METHODS: Eleven PKUpatients aged 27±10 years (1 HPA, 4 mild and 6 classical PKU) on dietary treatment were evaluated (anthropometry, body composition, blood pressure measurements, biochemical markers including vitamin, mineral, lipids, carbohydrates and protein status/metabolism, and nutritional intake assessment) at two different annual reviews. The mean time taking AA was 13±5 months and GMP 13±7 months. Blood phenylalanine (PHE) and tyrosine (TYR) were analysed before and after GMP introduction. RESULTS: Both GMP and AA protein substitutes provided similar protein equivalent intake (0.85 vs 0.75 g/kg/day, P=0.182). In the GMP group, it contributed 57% (27-100%) of the protein substitute intake (with AA delivering the rest of protein substitute intake), providing an additional 34±12 mg/day PHE. Nutritional intake, anthropometry and body composition measurements were similar in both the groups. Median blood PHE did not change (P=0.594), although values within target range improved (36 vs 46%), but this was not statistically significant. Mean blood TYR increased (52.0±19.2 vs 63.2±25.6 μmol/l, P=0.033), and all biochemical markers remained stable, except for a lower A1C haemoglobin (P=0.011). CONCLUSIONS: Partial GMP contribution to total protein substitute intake did not affect nutritional status in patients with PKU. Blood PHE control was not adversely affected. The increased blood TYR after GMP introduction necessitates further study.
Authors: Rianne Jahja; Stephan C J Huijbregts; Leo M J de Sonneville; Jaap J van der Meere; Francjan J van Spronsen Journal: J Pediatr Date: 2014-01-30 Impact factor: 4.406
Authors: Mercedes de Onis; Adelheid W Onyango; Elaine Borghi; Amani Siyam; Chizuru Nishida; Jonathan Siekmann Journal: Bull World Health Organ Date: 2007-09 Impact factor: 9.408
Authors: Kyungwha Lim; Sandra C van Calcar; Kathryn L Nelson; Sally T Gleason; Denise M Ney Journal: Mol Genet Metab Date: 2007-07-23 Impact factor: 4.797
Authors: M J Pena; M F de Almeida; E van Dam; K Ahring; A Bélanger-Quintana; K Dokoupil; H Gokmen-Ozel; A M Lammardo; A MacDonald; M Robert; J C Rocha Journal: Eur J Clin Nutr Date: 2016-04-27 Impact factor: 4.016
Authors: Nasser A Elhawary; Imad A AlJahdali; Iman S Abumansour; Ezzeldin N Elhawary; Nagwa Gaboon; Mohammed Dandini; Abdulelah Madkhali; Wafaa Alosaimi; Abdulmajeed Alzahrani; Fawzia Aljohani; Ehab M Melibary; Osama A Kensara Journal: Hum Genomics Date: 2022-07-19 Impact factor: 6.481
Authors: Bridget M Stroup; Denise M Ney; Sangita G Murali; Frances Rohr; Sally T Gleason; Sandra C van Calcar; Harvey L Levy Journal: J Nutr Metab Date: 2017-12-31
Authors: A Pinto; M F Almeida; A Cunha; C Carmona; S Rocha; A Guimas; R Ribeiro; C R Mota; E Martins; A MacDonald; J C Rocha Journal: Mol Genet Metab Rep Date: 2017-10-18
Authors: Kirsten K Ahring; Allan M Lund; Erik Jensen; Thomas G Jensen; Karen Brøndum-Nielsen; Michael Pedersen; Allan Bardow; Jens Juul Holst; Jens F Rehfeld; Lisbeth B Møller Journal: J Nutr Metab Date: 2018-01-08
Authors: Bridget M Stroup; Sangita G Murali; Denise J Schwahn; Emily A Sawin; Emma M Lankey; Hans Peter Bächinger; Denise M Ney Journal: Physiol Rep Date: 2019-10